| 摘要: |
| [摘要] 前列腺癌的进展与雄激素受体（androgen receptor，AR）以及AR反应通路相关，进展期前列腺癌患者需接受雄激素阻断治疗，而去势抵抗性前列腺癌（castration-resistant prostate cancer，CRPC）的临床治疗更加复杂。Enzalutamide，ARN-509，ONC1-13B三种新型AR拮抗剂是用于AR的靶向药物，临床研究正在进行中。AR拮抗剂效果明显且副作用小，因此应用这一类药物治疗CRPC的方法便日益凸显其重要性。 |
| 关键词: 去势抵抗性前列腺癌 雄激素受体拮抗剂 Enzalutamide ARN-509 ONC1-13B |
| DOI：10.11724/jdmu.2015.05.22 |
| 分类号: |
| 基金项目:基金项目：国家自然科学基金项目（31201070） |
|
| Advance of novel AR antagonists for castration-resistant prostate cancer treatment |
|
WANG Yu 1, XING Rong 2, WAN Shan-rong 1, WANG Yang 21,2
|
|
1. Department of Seven-Year Clinical Medicine, Dalian Medical University，Dalian 116044，China;2. Department of Pathophysiology，Dalian Medical University，Dalian 116044，China
|
| Abstract: |
| [Abstract] Prostate cancer is one of the common malignant tumors in male reproductive system. It is currently accepted that the progression of prostate cancer is related to androgen receptor (AR) and AR reaction pathway. The clinical treatment becomes more complicated when it progresses to castration-resistant prostate cancer (CRPC). The clinical trial have shown that three novel AR antagonists, including Enzalutamide, ARN-509and ONC1-13B, are effective and have minor adverse reactions. Therefore, application of AR antagonists in the treatment of CRPC is becoming increasingly important. |
| Key words: [Key words] castration-resistant prostate cancer AR antagonists Enzalutamide ARN-509 ONC1-13B |
